Andrew Reardon - May 9, 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Signature
/s/ Andrew Reardon
Stock symbol
LGND
Transactions as of
May 9, 2024
Transactions value $
-$307,749
Form type
4
Date filed
5/13/2024, 05:32 PM
Previous filing
Feb 29, 2024
Next filing
Jul 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $523K +10K +45.03% $52.27 32.2K May 9, 2024 Direct
transaction LGND Common Stock Sale -$830K -10K -31.05% $83.04 22.2K May 9, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -10K -13.71% $0.00 62.9K May 9, 2024 Common Stock 10K $52.27 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $83.00 to $83.27. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.